Avon rallies troops for Green Tomorrow
This article was originally published in The Rose Sheet
Executive Summary
Firm will leverage a "veritable green army" made up of its more than 6.2 million sales reps across the globe in "Hello Green Tomorrow" initiative aimed at raising awareness and funds to replant trees - at $1 a pop - in the South American Atlantic Rainforest. Avon will donate first $1 mil., according to March 16 release. While firm has "a long heritage" of giving back to community, raising more than $730 mil. through 2009 for breast cancer and domestic violence causes worldwide, Hello Green Tomorrow "marks the company's first external environmental engagement, and it underscores Avon's commitment to environmental stewardship." This month, the company also announced the Avon Paper Promise, with the goal of "purchas[ing] 100% of its paper from certified and/or post-consumer-recycled content sources within 10 years," it says
You may also be interested in...
Avon "Hello Green Tomorrow"
Firm has doubled its target under "Hello Green Tomorrow" campaign launched in March, announcing June 3 that it will use $2 mil. raised by its "veritable green army" to plant two million trees in South American Atlantic Rainforest. "The two million trees we are planting represent the initial milestone in what will be an ongoing global environmental mobilization effort," says President and CEO Andrea Jung. Avon's contribution will support the United Nations Environment Programme's "Plant for the Planet: Billion Tree Campaign," and restored forest will be monitored by The Nature Conservancy, Avon notes. Company is leveraging its "powerful woman-to-woman network" to raise not only funds but also awareness of "five simple things each and every one of us can do to improve the environment." HelloGreenTomorrow.com features tips for green living and information on the Atlantic Rainforest. While Avon has a history of giving back to its customers, recent initiatives have increased its environmental engagement (1"The Rose Sheet" March 22, 2010, In Brief)
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.